Meeting of the Uniform Formulary Beneficiary Advisory Panel, 62224 [07-5456]

Download as PDF 62224 Federal Register / Vol. 72, No. 212 / Friday, November 2, 2007 / Notices DEPARTMENT OF DEFENSE Office of the Secretary Meeting of the Uniform Formulary Beneficiary Advisory Panel Assistant Secretary of Defense (Health Affairs), Department of Defense. ACTION: Notice of meeting. pwalker on PROD1PC71 with NOTICES AGENCY: SUMMARY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the Government Act of 1976 (U.S.C. 522b, as amended) the Department of Defense announces the following Federal Advisory Committee Meeting. Name of Committee: Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). Date of Meeting: Thursday, January 10, 2008. Location: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004. Time: 8 a.m. to 4 p.m. Purpose of Meeting: The Panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform Formulary. Meeting Agenda: Sign-In; Welcome and Opening Remarks; Opportunity for Public Citizen Comments; Scheduled Therapeutic Class Reviews—Targeted Immunomodulatory Biologics (TIBs), BPH Alpha Blockers (BPH-ABs), Adrenergic Blocking Agents (ABAs) and Designated Newly Approved Drugs; Panel Discussions and Vote, and comments following each therapeutic class review. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165, and the availability of space this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing in. All persons must sign in legibly. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102.3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer. The Designated Federal Officer’s contact information can be obtained from the GSA’s FACA Database—https:// www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the scheduled meeting of the Panel VerDate Aug<31>2005 15:58 Nov 01, 2007 Jkt 214001 may be submitted at any time. However, if individual comments pertain to a specific topic being discused at a planned meeting then these statements must be submitted no later than five (5) business days prior to the meeting in question. The Designated Federal Officer will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set will set aside one (1) hour for individual or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice. Additionally, they will be afforded the opportunity to address the Panel. Registration for addressing the Panel in on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than five (5) minutes to present their comments, and at the end of the one (1) hour time period no further public comments will be accepted. FOR FURTHER INFORMATION CONTACT: Major Travis Watson, Designated Federal Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 5, Suite 810–5111 Leesburg Pike, Falls Church, Virginia 22041–3206, Telephone: (703) 681–2890—Fax: (703) 681–1940, E-mail Address: baprequests@tma.osd.mil. Dated: October 26, 2007. L.M. Bynum, Alternate OSD Federal Register Liaison Officer. [FR Doc. 07–5456 Filed 11–1–07; 8:45 am] BILLING CODE 5001–06–M ELECTION ASSISTANCE COMMISSION [Notice 2007–42] Consideration of Administrative Transfer of national Voter Registration Act Regulations Election Assistance Commission. ACTION: Notice: Request for Public Comment. AGENCY: SUMMARY: The Help America Vote Act of 2002 (Pub. L. 107–252, 116 Stat. 1727, 42 U.S.C. 15532) transferred authority to promulgate regulations under the National Voter Registration Act of 1993 (NVRA) (Pub. L. 93–31, 197 Stat. 77, 42 U.S.C. 1973gg–1 et. seq. at 41 U.S.C. 1973gg–7(a)) from the Federal Election Commission (FEC) to the Election Assistance Commission (EAC). The EAC is presently considering the PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 administrative transfer of NVRA regulations previously adopted and maintained by the FEC. These regulations are currently located at 11 CFR Part 8. In accordance with the Administrative Procedures Act (APA), this administrative transfer of the regulations would make no substantive changes to the FEC regulations and would be made without public comment. The only changes made would be technical, such as the address and contact information for the responsible agency. Following this administrative transfer of the regulations, the EAC would begin efforts to substantively amend the rules. This rulemaking process would include substantial public involvement, including public notice and comment pursuant to the APA. The EAC currently seeks public comment on whether the agency should administratively transfer regulations previously adopted and maintained by the FEC regarding the NVRA, currently located at 11 CFR Part 8, and then substantively amend those rules. Please note that the EAC does not seek substantive comment on the content of the existing regulations or potential modifications to the regulations. DATES: Comments must be received on or before 4 p.m. on December 3, 2007. ADDRESSES: Comments must be submitted in either electronic or written form. Comments may be submitted online at https://www.eac.gov. Commenters are encouraged to submit comments electronically to ensure timely receipt and consideration. Written comments should be sent to: NVRA Comments, Election Administration Support Division, U.S. Election Assistance Commission, 1225 New York Ave., NW., Suite 1100, Washington, DC 20005. FOR FURTHER INFORMATION CONTACT: Mr. ´ Edgardo Cortes, Election Research Specialist, (202) 566–3100 or toll-free (866) 747–1471. SUPPLEMENTARY INFORMATION: The National Voter Registration Act of 1993 (NVRA), Pub. L. 93–31, 197 Stat. 77, 42 U.S.C. 1973gg–1 et. seq, at 42 U.S.C. 1973gg–7(a) required the Federal Election Commission (FEC) to issue regulations to develop a national mail voter registration form for elections to Federal office, and to submit to Congress no later than June 30 of each odd-numbered year (beginning June 30, 1995) a report that assesses the impact of the NVRA and recommends improvements in Federal and State procedures, forms, and other matters affected by the NVRA. The FEC published an Advance Notice of E:\FR\FM\02NON1.SGM 02NON1

Agencies

[Federal Register Volume 72, Number 212 (Friday, November 2, 2007)]
[Notices]
[Page 62224]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-5456]



[[Page 62224]]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), Department of 
Defense.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the 
Government Act of 1976 (U.S.C. 522b, as amended) the Department of 
Defense announces the following Federal Advisory Committee Meeting.
    Name of Committee: Uniform Formulary Beneficiary Advisory Panel 
(hereafter referred to as the Panel).
    Date of Meeting: Thursday, January 10, 2008.
    Location: Naval Heritage Center Theater, 701 Pennsylvania Avenue 
NW., Washington, DC 20004.
    Time: 8 a.m. to 4 p.m.
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform 
Formulary.
    Meeting Agenda: Sign-In; Welcome and Opening Remarks; Opportunity 
for Public Citizen Comments; Scheduled Therapeutic Class Reviews--
Targeted Immunomodulatory Biologics (TIBs), BPH Alpha Blockers (BPH-
ABs), Adrenergic Blocking Agents (ABAs) and Designated Newly Approved 
Drugs; Panel Discussions and Vote, and comments following each 
therapeutic class review.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing in. All persons must sign in 
legibly.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102.3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer. The Designated Federal 
Officer's contact information can be obtained from the GSA's FACA 
Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discused at a planned meeting then 
these statements must be submitted no later than five (5) business days 
prior to the meeting in question. The Designated Federal Officer will 
review all submitted written statements and provide copies to all the 
committee members.
    Public Comments: In addition to written statements, the Panel will 
set will set aside one (1) hour for individual or interested groups to 
address the Panel. To ensure consideration of their comments, 
individuals and interested groups should submit written statements as 
outlined in this notice. Additionally, they will be afforded the 
opportunity to address the Panel. Registration for addressing the Panel 
in on a first-come, first-serve basis. Those wishing to address the 
Panel will be given no more than five (5) minutes to present their 
comments, and at the end of the one (1) hour time period no further 
public comments will be accepted.

FOR FURTHER INFORMATION CONTACT: Major Travis Watson, Designated 
Federal Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 
5, Suite 810-5111 Leesburg Pike, Falls Church, Virginia 22041-3206, 
Telephone: (703) 681-2890--Fax: (703) 681-1940, E-mail Address: 
baprequests@tma.osd.mil.

    Dated: October 26, 2007.
L.M. Bynum,
Alternate OSD Federal Register Liaison Officer.
[FR Doc. 07-5456 Filed 11-1-07; 8:45 am]
BILLING CODE 5001-06-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.